Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma

Radboud University Medical Center

Status: Completed

Conditions: Renal Cell Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00509704

CMO 2006/232

Details and patient eligibility

About

The purpose of the study is to assess the effect of Sunitinib on tumor vascularization and necrosis in patients with metastatic renal cell cancer.

Full description

Sutent is an angiogenesis inhibitor used in the treatment of renal cell cancer. Very often tumor necrosis is seen after the start of the treatment. It is unknown after how many days this effect starts. In patients with renal cell cancer with metastases, who will be treated with Sutent, 3 MRIs will be made. Kep, R2*, b-coefficient (perfusion, hypoxia, blood volume and necrosis) will be measured.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with metastatic renal cell cancer for whom treatment with Sunitinib is planned
• histologically verified stage IV renal cell carcinoma of clear cell type
• measurable primary tumor or metastases (minimal diameter 2 cm) at other sites than the lungs
• Karnofsky score > 70%
• age > 18 year.
• written informed consent

Exclusion criteria

• contra-indications for MRI
• contra-indications for treatment with Sunitinib
• previous systemic treatment within the last 30 days